Before the end of 2017, Teva Pharmaceutical Industries will be laying off more than 200 workers.
Currently employing 540 workers at its Bulebel plant and 180 workers in Hal Far, the company will be laying off approximately 210 workers between the two plants, respectively, as a result of its “European restructuring,” according to an article in Malta Today.
Earlier this year, Teva acquired Actavis Generics, strengthening its generics business through the acquisition of its competitor.
According to the article in Malta Today:
“But now, as part of a global restructuring — with the main changes affecting European plants — the company approved a decision to lay off workers to tackle operational overlaps.
Flanked by Malta Enterprise chairman Mario Galea and Jobsplus executive chairperson Clyde Caruana, Cardona and Bartolo said that a taskforce was immediately set up to identify the skills of the workers set to be made redundant and the job opportunities in the market.”
In addition, the company confirmed that all manufacturing operations at its Hal Far plant will be ceased at the end of the first quarter of 2018. Teva claims that both union and non-union positions will be affected in this change. As a result, the Bulebe facility will undergo a restructuring of its own—impacting 35 jobs in the first half of 2017.
“All other Teva functional activities, including Bulebel manufacturing operations, will continue in Malta,” Malta Today reports.
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
Filed Under: Drug Discovery
